image
Healthcare - Biotechnology - NASDAQ - US
$ 15.79
1.27 %
$ 1.4 B
Market Cap
-3.71
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one TVTX stock under the worst case scenario is HIDDEN Compared to the current market price of 15.8 USD, Travere Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one TVTX stock under the base case scenario is HIDDEN Compared to the current market price of 15.8 USD, Travere Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one TVTX stock under the best case scenario is HIDDEN Compared to the current market price of 15.8 USD, Travere Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart TVTX

image
$24.0$24.0$22.0$22.0$20.0$20.0$18.0$18.0$16.0$16.0$14.0$14.0$12.0$12.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
233 M REVENUE
60.55%
-321 M OPERATING INCOME
14.89%
-321 M NET INCOME
14.80%
-237 M OPERATING CASH FLOW
15.19%
99.3 M INVESTING CASH FLOW
78.08%
139 M FINANCING CASH FLOW
-36.26%
74.8 M REVENUE
18.90%
-60.7 M OPERATING INCOME
-10.93%
-60.3 M NET INCOME
-10.07%
-35.7 M OPERATING CASH FLOW
15.97%
-80.3 M INVESTING CASH FLOW
-174.11%
139 M FINANCING CASH FLOW
302332.61%
Balance Sheet Travere Therapeutics, Inc.
image
Current Assets 417 M
Cash & Short-Term Investments 371 M
Receivables 27.1 M
Other Current Assets 18.9 M
Non-Current Assets 177 M
Long-Term Investments 0
PP&E 19.6 M
Other Non-Current Assets 158 M
62.39 %4.56 %3.18 %3.30 %26.56 %Total Assets$594.1m
Current Liabilities 201 M
Accounts Payable 23.5 M
Short-Term Debt 74.1 M
Other Current Liabilities 103 M
Non-Current Liabilities 334 M
Long-Term Debt 328 M
Other Non-Current Liabilities 6.8 M
4.40 %13.85 %19.28 %61.21 %Total Liabilities$535.0m
EFFICIENCY
Earnings Waterfall Travere Therapeutics, Inc.
image
Revenue 233 M
Cost Of Revenue 0
Gross Profit 233 M
Operating Expenses 557 M
Operating Income -321 M
Other Expenses 0
Net Income -321 M
300m300m200m200m100m100m00(100m)(100m)(200m)(200m)(300m)(300m)(400m)(400m)233m0233m(557m)(321m)0(321m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
-137.51% OPERATING MARGIN
-137.51%
-137.90% NET MARGIN
-137.90%
-544.28% ROE
-544.28%
-54.12% ROA
-54.12%
-68.62% ROIC
-68.62%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Travere Therapeutics, Inc.
image
00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)(350m)(350m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -321 M
Depreciation & Amortization 43.6 M
Capital Expenditures -101 M
Stock-Based Compensation 36.9 M
Change in Working Capital 0
Others 2.69 M
Free Cash Flow -339 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Travere Therapeutics, Inc.
image
Wall Street analysts predict an average 1-year price target for TVTX of $21.9 , with forecasts ranging from a low of $12 to a high of $33 .
TVTX Lowest Price Target Wall Street Target
12 USD -24.00%
TVTX Average Price Target Wall Street Target
21.9 USD 38.84%
TVTX Highest Price Target Wall Street Target
33 USD 108.99%
Price
Max Price Target
Min Price Target
Average Price Target
35353030252520201515101055Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 17
6. Ownership
Insider Ownership Travere Therapeutics, Inc.
image
Sold
0-3 MONTHS
3.37 M USD 8
3-6 MONTHS
1.21 M USD 8
6-9 MONTHS
1.59 M USD 8
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on April 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 31,100 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted as. businesswire.com - 3 weeks ago
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025 SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere's late-breaking oral presentation at NKF details partial and complete proteinuria remission data from the DUPLEX Study of FILSPARI in FSGS. businesswire.com - 1 month ago
Two S&P 500 Giants And Biotech Play Lead Five Stocks To Watch As Market Struggles The stock market is attempting to rebound amid President Donald Trump's trade war. The post Two S&P 500 Giants And Biotech Play Lead Five Stocks To Watch As Market Struggles appeared first on Investor's Business Daily. investors.com - 1 month ago
Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS sNDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS If approved, FILSPARI could become the first and only FDA-approved treatment for FSGS, a rare kidney condition and a leading cause of kidney failure Additionally, the FDA notified the Company that REMS monitoring for embryo-fetal toxicity is no longer necessary; the Company plans to submit an amendment to the REMS sNDA currently under review for modification of liver monitoring SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced the Company has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking priority review for traditional approval of FILSPARI® (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS). The submission is supported by results from the Phase 3 DUPLEX Study and the Phase 2 DUET Study, two of the largest head-to-head interventional studies conducted to date in adult and pediatric patients with FSGS. globenewswire.com - 1 month ago
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, March 12, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on March 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 77,200 shares of its common stock to five new employees, consisting of inducement stock options to purchase an aggregate of 36,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 41,200 shares of its common stock. These inducement stock options and inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4). globenewswire.com - 1 month ago
Travere Therapeutics to Participate at Upcoming Investor Conferences SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences in March: globenewswire.com - 2 months ago
Travere Therapeutics, Inc. (TVTX) Q4 2024 Earnings Call Transcript Travere Therapeutics, Inc. (NASDAQ:TVTX ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Victoria Prescott - Manager of Investor Relations Eric Dube - President and CEO Jula Inrig - Chief Medical Officer Peter Heerma - Chief Commercial Officer Chris Cline - CFO William Rote - Senior Vice President of Research & Development Conference Call Participants Malcolm Kuno - JPMorgan Vamil Divan - Guggenheim Securities Joseph Schwartz - Leerink Partners Liisa Bayko - Evercore ISI Yigal Nochomovitz - Citigroup Prakhar Agrawal - Cantor Fitzgerald Fadi Ahman - Wells Fargo Gregory Harrison - Scotiabank Jason Zemansky - BofA Securities Alexander Thompson - Stifel Ed Arce - H.C. Wainwright Operator Good afternoon, and welcome to the Travere Therapeutics Fourth Quarter and Full Year 2024 Financial Results Conference Call. seekingalpha.com - 2 months ago
Compared to Estimates, Travere (TVTX) Q4 Earnings: A Look at Key Metrics The headline numbers for Travere (TVTX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com - 2 months ago
Travere Therapeutics (TVTX) Reports Q4 Loss, Tops Revenue Estimates Travere Therapeutics (TVTX) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to loss of $1.16 per share a year ago. zacks.com - 2 months ago
Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results Company to submit sNDA around the end of 1Q 2025 seeking traditional approval of FILSPARI ® (sparsentan) for FSGS globenewswire.com - 2 months ago
Curious about Travere (TVTX) Q4 Performance? Explore Wall Street Estimates for Key Metrics Get a deeper insight into the potential performance of Travere (TVTX) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics. zacks.com - 2 months ago
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results SAN DIEGO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2024 financial results on Thursday, February 20, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. globenewswire.com - 2 months ago
8. Profile Summary

Travere Therapeutics, Inc. TVTX

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 1.4 B
Dividend Yield 0.00%
Description Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Contact 3611 Valley Centre Drive, San Diego, CA, 92130 https://www.travere.com
IPO Date Nov. 8, 2012
Employees 385
Officers Ms. Angela Giannantonio Chief People Officer Mr. Peter Heerma Chief Commercial Officer Mr. Casey Logan Chief Business Officer Dr. Eric M. Dube Ph.D. President, Chief Executive Officer & Director Ms. Nivi Nehra Vice President of Corporate Communications & Investor Relations Dr. Jula Inrig M.D. Chief Medical Officer Ms. Elizabeth E. Reed J.D. Chief Legal Officer, General Counsel & Secretary Dr. William E. Rote Ph.D. Chief Research Officer Ms. Sandra Calvin SVice President, Corporate Controller & Chief Accounting Officer Mr. Christopher Cline C.F.A. Chief Financial Officer